Commentary on “Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach” ‐ Will we ever be able to avoid inhibitor formation in hemophilia A?

Inhibitory antibody formation against infused therapeutic factor VIII (FVIII) concentrates remains an important and unresolved risk in treatment of hemophilia A (HA). Both severe and nonsevere HA have substantial risk of inhibitor occurrence.1-4 Inhibitor occurrence in severe HA has been a major focus of epidemiological, immunological, and genomic studies over past decades. Despite these major collaborative studies identifying candidate gene...